Pharma RSS Digest - 2026-08-08
Overview
The tape is light but produces two substantive company-specific stories, both filed on August 6, 2026. Cryoport delivered a Q2 earnings beat paired with profitability progress and fresh customer regulatory wins in cell and gene therapy, reinforcing tailwinds across the CGT supply chain. MetaVia advanced its lead obesity candidate into the highest-dose cohorts of a Phase 1 study, positioning a pivotal Q4 readout for a small-cap story in a crowded GLP-1-adjacent field. The wider news flow thinned out beyond these names — a safety recall of neonatal respiratory hardware and a consolidation move in CGT bioprocessing round out the watchlist.
Key Developments
Cryoport reported Q2 2026 revenue of approximately $49.0 million, up 8% year-over-year, with growth concentrated in Life Sciences Services (+15%), and BioStorage/BioServices posting the fastest segment gain at +25%. The company also reached positive adjusted EBITDA for the quarter, framed by management as a key profitability milestone after years of investment, while Life Sciences Products revenue was flat, hinting at softer cryogenic-systems demand. Customer-side momentum strengthened the commercial narrative: Orca Bio's TREGZI received FDA approval, Vertex's CASGEVY was expanded to pediatric patients as young as two, and four customers filed BLAs/MAAs during the quarter with additional approvals anticipated before year-end. Watch next: the remaining 2026 BLA/approval slate (roughly 11 filings and 5 possible approvals), the official launch scope of the Paris Global Supply Chain Center (the release was truncated), and whether Life Sciences Products re-accelerates in the back half.
MetaVia announced that all active patients in the DA-1726 Phase 1 Part 3 study successfully reached the highest planned dose levels (48 mg and 64 mg), setting up a 16-week topline readout in Q4 2026. Prior 8-week data at the 48 mg dose showed up to 9.1% mean body weight reduction without evidence of a plateau — an encouraging signal in a competitive GLP-1/glucagon dual-agonist landscape where differentiation on durability and tolerability is hard to come by. Separately, the company is working toward an End-of-Phase 2 FDA meeting in H2 2026 for vanoglipel (DA-1241) in MASH, with preclinical combination data alongside resmetirom and metformin generating early scientific interest. Watch next: the Q4 DA-1726 readout as the central catalyst, the scheduled timing of the vanoglipel FDA meeting, and any commentary on cash runway as Q2 R&D spend rose to roughly $3.5 million from $2.3 million a year earlier.
Watchlist
- Medline neonatal breathing circuit recall — Nationwide recall of 18 SKUs of Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits over a connector overheating defect; failure rate reported at 0.011% with no serious injuries to date, but the five-year distribution window leaves a large installed base. [link]
- BioLife Solutions / Repligen acquisition — BioLife posted Q2 revenue of $28.5 million (+21%) alongside the announced ~$1.5 billion Repligen deal; GAAP net income of $45.1 million was inflated by a one-time $42.4 million non-cash tax benefit, and the deal still needs shareholder and regulatory clearance for a targeted Q4 2026 close. [link]
- David Sinclair launches Lifespan platform — Boston-based media venture pairing a longevity magazine, a podcast community, and a nonprofit funding arm; commercial terms, membership pricing, and foundation grant details were not disclosed. [link]
- IM Cannabis convertible note financing — Suppressed from the main digest due to thin disclosure; a modest raise of $250,000 in gross proceeds is unlikely to be market-moving on its own.